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Abstract
Background: Studies have shown that zinc and selenium 
deficiency is common in nonalcoholic fatty liver disease 
(NAFLD). However, the effects of zinc and selenium 
co-supplementation before and/or after disease progression 
on NAFLD are not clear enough. The aim of this study was to 
compare the effects of zinc and selenium co-supplementation 
before and/or after disease progression on NAFLD prognosis.
Methods: Forty male Sprague–Dawley rats (197±4 g) were 
randomly assigned to 4 dietary groups: normal-fat diet (NFD; 
receiving 9% of calories as fat), high-fat diet (HFD; receiving 
82% of calories as fat), supplementation before disease 
progression (S+HFD), and supplementation after disease 
progression (HFD+S). The diets were implemented over a 
20-week period in all the groups. Biochemical and histologic 
parameters were compared between the 4 groups, and between-
group comparisons were also carried out.
Results: There were significant differences in the average food 
dietary intake (P<0.001), weight (P<0.001), fasting blood sugar 
(P=0.005), triglyceride (P<0.001), total cholesterol (P<0.001), 
low-density lipoprotein cholesterol (P=0.002), high-density 
lipoprotein cholesterol (P=0.001), alanine aminotransferase 
(P<0.001), and aspartate aminotransferase (P<0.001) between 
the 4 dietary groups. Serum triglyceride and total cholesterol 
were significantly lower in the HFD+S Group than in the S+HFD 
Group (P<0.001 and P=0.003, respectively). Fat accumulation 
was significantly reduced in the HFD+S Group (P<0.001).
Conclusion: Zinc and selenium co-supplementation after disease 
progression improved biochemical and histologic parameters in 
an experimental model of NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common 
metabolic disease and afflicts 20%–30% of people in Western 
countries and 15% of people in Asia.1,2 NAFLD is defined as 
triglyceride (TG) accumulation exceeding 5% of the liver weight.3 
Disease progression has a direct link with visceral obesity, glucose 
intolerance, and dyslipidemia.4 The pathogenesis of NAFLD is 
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What’s Known
• Molecular and cellular studies 
have shown that zinc and selenium 
supplementation can be protective 
in rodent models of type 2 diabetes 
by stimulating insulin secretion and 
lowering serum glucose and insulin 
levels.
•	 Zinc	 and	 selenium	 deficiency	
is common in nonalcoholic fatty liver 
disease.
What’s New
• Nonalcoholic fatty liver disease 
is	an	 inflammatory	disorder,	 leading	 to	
mineral	deficiency	in	the	liver	and	blood.	
• Zinc and selenium co-
supplementation can reverse the 
disease progression by improving 
serum biochemical parameters (e.g., 
lipid	profile	and	liver	enzyme	tests)	and	
fat granule accumulation and size in the 
liver.
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unknown; be that as it may, a mechanism that may 
be involved is liver injury mediated by endotoxins/
cytokines, oxidative stress, and hyperinsulinemia.3 
Zinc is an important micronutrient in that it plays 
a key role in the metabolism of macronutrients,5 
as well as the synthesis, storage, release, 
and actions of insulin.6 Molecular and cellular 
studies have shown that zinc and selenium 
supplementation can be protective in rodent 
models of type 2 diabetes by stimulating insulin 
secretion and lowering serum glucose and insulin 
levels.7,8 According to previous studies, zinc and 
selenium deficiency is common in cirrhosis and 
can affect nitrogen metabolism.9,10
The relationship between zinc/selenium 
intake and chronic fatty liver disease is complex 
as zinc/selenium affects the normal functioning 
of the liver and the liver plays a central role in 
zinc/selenium hemostasis; accordingly, the 
deficiencies of these minerals damage liver 
function and compromise the recovery and 
restoration of liver tissues.11
To our knowledge, no human or animal 
studies have been performed to study the effects 
of zinc supplementation in combination with 
selenium, before and after disease progression, 
on the prognosis of NAFLD. So, the aim of 
this study was to compare the effects of zinc 
supplementation with selenium before and/
or after disease progression on the prognosis 
of NAFLD based on serum glucose, lipid 
profile, hepatic enzymes, and histology in an 
experimental model of Sprague–Dawley rats.
Materials and Methods
Animals, Diets, Interventions, and Experimental 
Design
The experimental protocol was approved by 
the Iran National Science Foundation, Tehran, 
Iran (protocol #91056877). This research 
conforms to the Institutional and National Guide 
for the Care and Use of Laboratory Animals. 
Forty male Sprague–Dawley rats (197±4 g) 
were obtained from the Razi Vaccine and 
Serum Research Institute, Tehran, Iran. The 
rats were housed at 21–23°C and controlled 
humidity (50±5%) under a 12-hour artificial 
light cycle (7 am to 7 pm). All the animals had 
ad libitum access to water and the AIN93M diet 
1 week before the commencement of the study 
for adaptation. Then, the rats were randomly 
assigned to 4 different groups (figure 1). The 
ingredients of the AIN93M diet are depicted in 
table 1.
The rats on high-fat diet were supplemented 
with zinc sulfate (ZnSO4) and sodium selenite 
in the 1st 8 weeks and/or in the last 8 weeks 
of the study. Supplementation was done 
with ZnSO4 (15 mg/kg)10 and sodium selenite 
(2.5 mg/kg)12 solutions in distilled water daily by 
intragastric administration. The animals were 
weighed on a calibrated balance scale (Marte 
Scale, EK-3000i, USA) to the nearest 0.1 g 
weekly for the determination of weight changes.
The animals were thereafter sacrificed after 
20 weeks of intervention using 80 mg/kg of 
Figure 1: Schematic overview of the experimental study design. The high-fat diet (HFD) group was assigned to 3 groups: 1 group 
received the high-fat diet over a 20-week period without any supplementation; 1 group received zinc and selenium co-supplements 
in the 1st 8 weeks; and 1 group received zinc and selenium co-supplements in the last 8 weeks of the study.
Table 1: Composition of the experimental diets (per 1 kg) 
during the study period (AIN93M diet)
 Diets nutrients NFD HFD
Casein (g/kg) 140 180
Cornstarch (g/kg) 630 50
Sucrose (g/kg) 100 10
Soy oil (g/kg) 40 21
SFA1 (g/kg) - 483
Fiber (g/kg) 50 50
Mineral mix (g/kg) 35 35
Vitamin mix (g/kg) 10 10
L-cys2 (g/kg) 1.8 1.8
Choline bitartrate (g/kg) 2.5 2.5
tert-Butylhydroquinone (g/kg) 0.008 0.008
Energy (kcal/g) 3.8 5.5
As carbohydrate (%) 76 5
As fat (%) 9 82
As protein (%) 15 13
NFD: Normal AIN93M diet; HFD: High-fat AIN93M diet; 
1SFA, Saturated fatty acid as lard; 2L-cys, L- cysteine
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ketamine and 10 mg/kg of xylazine. Fasting 
blood samples were collected in a tube with 
EDTA, centrifuged at 1000 g for 20 minutes, and 
plasma was separated and stored at -70°C until 
the biochemical analyses.
Biochemical Parameters Measurement
The blood levels of total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), and TG 
were measured photometrically in an automatic 
analyzer (Cobas Integra 400, Roche, Mannheim, 
Germany). Fasting blood glucose was measured 
via an enzymatic method (Pars Azmoon Co. 
kit, Tehran, Iran) using a Liasys AutoAnalyzer. 
Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured via the 
spectrophotometry method (Pars Azmoon Co. Kit, 
Tehran, Iran). The selenium and zinc concentrations 
of the serum and liver were measured using an 
atomic absorption spectrophotometer (Perkin 
Elmer 2100B, Germany).
Histological Assessment
The hematoxylin and eosin (H & D) stain 
method was used for histological analysis and 
evaluated by a pathologist in a blinded manner. 
Parts of hepatic lobes were removed from each 
animal and were fixed in a 10% formaldehyde 
buffer. Then, the samples were dehydrated in 
ascending grades of alcohol and embedded in 
paraffin. Sections at 5-Mm thickness were taken 
and stained with hematoxylin and eosin. Images 
were captured at 400× magnification and were 
analyzed using the Image-Portlab software. 
According to the H & D method, fat accumulation 
was classified as stage 0 (<5% of fat accumulation), 
stage 1 (5%–33% of fat accumulation), stage 
2 (34%–66% of fat accumulation), and stage 3 
(>66% of fat accumulation in the liver cells).13
Statistical Analysis
All the data are expressed as mean ± 
standard deviation (SD). The level of significance 
was set at a P<0.05. The statistical analyses 
were performed with IBM SPSS Statistics 
software (version 16; IBM Corp.). Normal 
distribution in the variables was checked using 
the Kolmogorov–Smirnov test. The continuous 
variables were compared between the groups 
using the ANOVA, followed by the post-hoc test 
to compare the between-group differences.
Results
Serum Biochemical Parameters Measurements
Our results showed that there were significant 
differences in the average of dietary intake, 
weight, and all the biochemical parameters 
between the 4 groups (P<0.01). Although dietary 
intake (g/d) was significantly higher in the NFD 
Group than in the HFD Group (P<0.001), the 
rats in the HFD Group significantly received 
more calories than those in the NFD Group 
(P<0.001). Fasting blood sugar (P=0.01), TG 
(P<0.001), TC (P<0.001), LDL-C (P=0.001), ALT 
(P<0.001), and AST (P=0.002) were significantly 
higher in the HFD Group than in the NFD Group. 
The serum and liver levels of zinc and selenium 
were significantly higher in the NFD Group than 
in the HFD Group (P<0.001 in all comparisons).
Co-supplementation with zinc and selenium 
after disease progression (HFD+S) significantly 
decreased the serum levels of fasting blood 
sugar (P=0.01), TG (P<0.001), TC (P=0.001), 
LDL-C (P<0.001), ALT (P<0.001), and AST 
(P=0.002). Nonetheless, before disease 
co-supplementation (S+HFD) decreased 
only the serum levels of TG (P=0.04), ALT 
(P<0.001), and AST (P<0.001) compared with 
the HFD Group. The serum TG and TC levels 
in the HFD+S Group were significantly lower 
than those in the S+HFD Group (P<0.001 and 
P=0.003, respectively). The serum and liver 
levels of zinc and selenium were significantly 
higher in the supplemented groups (S+HFD 
and HFD+S) than in the HFD Group (P<0.001). 
Serum zinc and selenium, as well as liver zinc 
levels, were significantly higher in the S+HFD 
Group than in the HFD+S Group (P<0.001 in all 
comparisons), while the liver level of selenium in 
the HFD+S Group was significantly higher than 
that in the S+HFD Group (P<0.001) (table 2).
Histological Analysis
As is shown in figure 2, more and lager fat 
granules were obtained in the HFD Group as a 
model for NAFLD progression. Thirty percent of 
liver cells were accumulated by fat granules in 
the HFD Group, compared with the NFD Group. 
The fat accumulation rate in the S+HFD Group 
and the HFD+S Group was 15.36% and 4.7%, 
correspondingly. Co-supplementation with 
zinc and selenium after disease progression 
(HFD+S) significantly decreased the size and 
number of fat granules in the liver compared 
with the HFD Group. Also, fat granules were 
significantly smaller and fewer in the liver of the 
HFD+S Group than in the liver of the S+HFD 
Group (P<0.001) (figure 2).
Discussion
Recently a published meta-analysis14 and 
a review15 reported controversial results 
regarding the treatment of NAFLD. Various 
 Supplementation in fatty liver
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pharmacologic approaches focusing on weight 
reduction and reversal of insulin resistance 
were mentioned, either by lifestyle intervention 
alone or in combination with pharmacotherapy. 
However, besides sustained weight loss, no 
other single intervention has exhibited explicit 
statistically significant efficacy in the treatment 
of NAFLD. This highlights the need for novel 
approaches to the prevention and treatment 
of NAFLD. To our knowledge, the present 
study is the 1st animal research to compare the 
effects of zinc and selenium supplementation, 
before and/or after NAFLD progression, on 
serum glucose, lipid profile, hepatic enzymes, 
and fat accumulation. By feeding rats a high-
fat diet (containing 82% of calories as fat), we 
induced marked hepatic lipid accumulation as 
assessed both by serum biochemical analysis 
and by histopathologic analysis. Our results 
demonstrated that a combination of zinc and 
selenium supplementation after fatty liver 
disease progression had better effects than 
before disease progression on serum glucose, 
lipid profile, and hepatic fat accumulation. 
Previous studies have shown that serum and liver 
zinc concentrations were significantly reduced in 
patients with alcoholic steatosis, hepatitis, and 
cirrhosis.16 Animal studies have demonstrated 
that dietary zinc supplementation attenuates 
alcohol-induced liver injury,17,18 suggesting the 
importance of zinc in the progression of alcoholic 
Table 2: Effects of 8 weeks’ zinc and selenium co-supplementation on the body measurements and serum biochemical 
parameters of the rats with fatty liver induced by 12 weeks of a high-fat diet
 Groups variables n=10 P value†
NFD HFD S+HFD HFD+S
Weight (g)
-beginning 197±4 196±3 193±4 193±5 0.89
-end of studya 342±6* 358±14* 362±6* 360±5* <0.001
Liver (g) 7.5±4 7.8±2 7.6±0.2 7.8±0.2 0.92
Average food intake
g/da 13±0.5 10±0.4 10.1±0.5 10.1±0.4 <0.001
kcal/da 49.4±1.9 55±2.2 55.5±2.75 55.5±2.2 <0.001
FBS (mg/dL)a,c 88.4±24.7 167.5±86.7 197.8±45.2 96.4±30.7 0.005
TG (mg/dL)a,b,c d 59.1±10.7 82.6±18.7 67.6±7.8 41.3±11.4 <0.001
TC (mg/dL)a,c,d 75±6.5 101.2±12.1 91.1±10.8 74.9±10.7 <0.001
LDL-C (mg/dL)a,c 36.7±5.9 52.1±12.2 43.4±13.1 31.4±14.1 0.002
HDL-C (mg/dL) 26.2±2.9 31.9±3.2 34.3±3.3 35.9±8.7 0.001
ALT (IU/l)a,b,c 71.4±14.3 149±13.3 95.6±19.7 99.3±22.2 <0.001
AST (IU/L)a,b,c 115.3±40.3 198.7±21.1 124.7±11.4 141.2±46.2 <0.001
Serum Zn (µg/dL)a,b,c,d 78±4.6 33±7 97±4 56±5 <0.001
Serum Se (µg/dL)a,b,d 8.8±1.5 5.5±2.3 12.4±1.3 6.4±3.1 <0.001
Liver Zn (µg/g)a,b,c,d 101±2.6 54.2±7 111±1.5 73.7±12 <0.001
Liver Se (µg/g)a,b,c,d 5.6±1.08a 2.2±1.07a,b,c 7.7±1.02b,d 11.2±1.25c,d <0.001
cholesterol; TG: Triglyceride; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; ALT: Alanine aminotransferase; 
AST: Aspartate amino transferase; NFD: Normal AIN93M diet throughout the study; HFD: High-fat AIN93M diet throughout the 
study; S+HFD: Zinc and selenium co-supplementation at the beginning of the study and before disease progression; HFD+S: 
Zinc and selenium co-supplementation after disease progression; asignificant difference between the NFD and HFD groups; 
bsignificant difference between the HFD and S+HFD groups; csignificant difference between the HFD and HFD+S groups; 
dsignificant difference between the S+HFD and HFD+S groups; *P<0.05 as compared with baseline within the groups, values 
are reported as mean±SD. †One-way ANOVA, followed by post-hoc test, was used. (Significance was considered at a P<0.05.) 
TC: Total
Figure 2: Micrographs show typical hepatic steatosis in the 
high-fat AIN93M group with a mass of more and larger fat 
granules. In contrast, fewer and smaller fat granules are 
observed in the HFD+S Group than in the HFD Group and the 
S+HFD Group. A: Normal-fat diet (NFD) group, B: High-fat 
diet (HFD) group, C: Zinc and selenium co-supplementation 
in the 1st 8 weeks of the study, before disease progression 
(S+HFD), D: Zinc and selenium co-supplementation in the 
last 8 weeks of the study, after disease progression (HFD+S).
DC
BA
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liver disease. While the link between zinc and 
selenium supplementation before and after 
NAFLD progression has not been determined, 
increasing evidence suggests that zinc plays 
a critical role in the regulation of hepatic lipid 
metabolism.19
In our study, zinc and selenium 
co-supplementation decreased serum lipid 
profile, as well as hepatic fat accumulation, 
after disease progression, while it had no 
more effects before disease creation because 
infection and inflammation significantly reduce 
the blood levels of zinc in chronic liver diseas.9 
Stress hormones and pro-inflammatory markers 
such	as	tumor	necrosis	factor-α	lead	to	change	
in zinc metabolism.20 On the other hand, blood 
selenium levels decrease in chronic liver 
disease.10 Thus, supplementation after disease 
progression exerts more significant effects due 
to the depletion of micronutrients.
Hyperglycemia increases the glycation of 
lipoproteins, including LDL and HDL, associated 
with the elevation of TG levels in the blood 
through increased synthesis from glucose and 
impaired lipid metabolism.21
In a human study in the U.K., researchers 
showed that higher serum selenium levels were 
associated with increased total and non-HDL-C 
levels, but not with HDL-C. These findings raise 
additional concern about the potential adverse 
lipid profile levels of high selenium status.22 
Our study showed that zinc and selenium 
co-supplementation led to a reduction in disease 
progression, but it had no effect before disease 
progression. These results may be due to 
depletion in zinc and selenium resulting from 
fatty liver disease.
To the best of our knowledge, the current 
study is the 1st animal investigation to assess 
the effect of zinc supplementation with selenium 
on the prognosis of fatty liver disease, before 
and after disease progression. In our study, 
supplementation after disease progression 
improved serum glucose, lipid profile, and 
hepatic enzymes and histology. We created 
stage 1 of fatty liver with a high-fat diet. This 
is an animal model and, therefore, the effects 
of the diets cannot be directly transposed to 
humans. Rather, this study provides indications 
vis-à-vis the possible effects of such dietary 
manipulations on NAFLD progression and may, 
as such, suggest future insights for research into 
the underlying mechanisms.
Conclusion
NAFLD is an inflammatory disorder and leads 
to mineral deficiency in the liver and blood. Zinc 
and selenium co-supplementation after disease 
progression can reverse the progression by 
improving serum biochemical parameters 
(e.g. lipid profile and liver enzyme tests) and fat 
granule accumulation and size in the liver.
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